OptimizeRx (NASDAQ:OPRX) Announces Quarterly Earnings Results, Beats Expectations By $0.05 EPS

OptimizeRx (NASDAQ:OPRX) posted its quarterly earnings data on Wednesday. The company reported $0.16 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.11 by $0.05, FiscalAI reports. OptimizeRx had a return on equity of 10.86% and a net margin of 6.37%.The company had revenue of $20.50 million for the quarter, compared to analysts’ expectations of $20.20 million.

Here are the key takeaways from OptimizeRx’s conference call:

• Q2 revenue fell 30% year over year to $20.5 million, while adjusted EBITDA declined to $4.9 million; management attributed the weakness to a few large customers, lower-margin managed services roll-off, macroeconomic pressures, and MFN-related spending caution.
• OptimizeRx reiterated full-year 2026 guidance for revenue of $95 million-$100 million and adjusted EBITDA of $21 million-$25 million, with revenue expected to be heavily weighted toward the second half and Q4 representing 35%-40% of annual revenue.
• Margin performance and cash generation improved despite lower revenue: gross margins are now expected to normalize in the high-60% to low-70% range, first-half operating cash flow was $8.1 million, and debt was reduced to $19.7 million at quarter-end, with an additional $3 million paid down afterward.
• The company reported growing adoption of its AI-enabled offerings, including Dynamic Audience Activation, which increased more than 30% year over year, and AI software revenue, which rose 25%; new launches include DeepIntent programmatic integration, the Natural Language Audience Builder, and CopayCue.
• DeepIntent integration is now live and generating bid flow, potentially expanding access to programmatic healthcare advertising budgets, while management also announced that Andy D’Silva will become CFO on January 1, 2027, succeeding Edward Stelmakh after a planned transition.

OptimizeRx Trading Up 1.7%

Shares of OptimizeRx stock opened at $7.04 on Thursday. OptimizeRx has a 1-year low of $4.54 and a 1-year high of $22.25. The company has a debt-to-equity ratio of 0.16, a current ratio of 5.37 and a quick ratio of 5.37. The stock has a market cap of $132.07 million, a P/E ratio of 20.11 and a beta of 1.08. The stock’s 50 day simple moving average is $5.97 and its 200-day simple moving average is $6.74.

Institutional Trading of OptimizeRx

Large investors have recently added to or reduced their stakes in the stock. Quantbot Technologies LP purchased a new position in shares of OptimizeRx during the 2nd quarter worth $44,000. BNP Paribas Financial Markets boosted its position in shares of OptimizeRx by 119.2% during the 2nd quarter. BNP Paribas Financial Markets now owns 4,074 shares of the company’s stock valued at $55,000 after acquiring an additional 2,215 shares during the last quarter. Worth Venture Partners LLC purchased a new stake in shares of OptimizeRx in the third quarter valued at about $220,000. ExodusPoint Capital Management LP purchased a new stake in shares of OptimizeRx in the fourth quarter valued at about $150,000. Finally, Campbell & CO Investment Adviser LLC acquired a new stake in OptimizeRx during the fourth quarter worth about $158,000. 76.47% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about OptimizeRx

Here are the key news stories impacting OptimizeRx this week:

• Positive Sentiment: Q2 earnings exceeded expectations: OptimizeRx reported adjusted earnings of $0.16 per share, above the $0.11 analyst consensus. Revenue of $20.5 million also topped estimates of $20.2 million, although EPS declined from $0.24 a year earlier. OptimizeRx Corp. Q2 Earnings and Revenues Top Estimates
• Positive Sentiment: Full-year outlook was maintained: Management reaffirmed 2026 revenue guidance of $95 million to $100 million and adjusted EBITDA guidance of $21 million to $25 million. The revenue range brackets the $97.5 million consensus estimate, reducing concerns about another outlook cut. OptimizeRx Reports Second Quarter 2026 Financial Results and Updates Fiscal Year 2026 Guidance
• Positive Sentiment: Debt refinancing strengthens liquidity: OptimizeRx completed a $35 million traditional banking facility, consisting of a $25 million term loan and a $10 million undrawn revolver. The company has repaid $8.3 million of principal since inception, potentially reducing financial pressure and preserving cash access. OptimizeRx Q2 Financial Results and Guidance
• Neutral Sentiment: Q2 adjusted EBITDA was $4.9 million, but the company recorded a $0.7 million net loss. The results show solid operating profitability before adjustments but continued bottom-line volatility. OptimizeRx Quarterly Earnings Results
• Negative Sentiment: Revenue guidance implies limited near-term growth visibility, while lower EPS versus last year and the quarterly net loss may temper enthusiasm despite the earnings beat.

Analyst Ratings Changes

OPRX has been the topic of several research reports. Wall Street Zen downgraded OptimizeRx from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 20th. Lake Street Capital dropped their price target on OptimizeRx from $20.00 to $11.00 and set a “buy” rating for the company in a research report on Wednesday, May 13th. Stephens reduced their price objective on OptimizeRx from $10.00 to $7.00 and set an “equal weight” rating for the company in a research note on Wednesday, May 13th. Zacks Research lowered OptimizeRx from a “strong-buy” rating to a “hold” rating in a report on Monday, May 4th. Finally, Stifel Nicolaus decreased their price objective on OptimizeRx from $17.00 to $14.00 and set a “buy” rating on the stock in a report on Wednesday, May 13th. Six investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, OptimizeRx presently has a consensus rating of “Moderate Buy” and an average price target of $13.43.

OptimizeRx Company Profile

OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.